Vitrolife Yönetim

Yönetim kriter kontrolleri 2/4

Vitrolife CEO'su Bronwyn Brophy O´Connor, Aug2023 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı SEK 7.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 74.5% maaş ve 25.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.014% ine doğrudan sahiptir ve bu hisseler € 372.50K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 6.8 yıldır.

Anahtar bilgiler

Bronwyn Brophy O´Connor

İcra Kurulu Başkanı

SEK 7.4m

Toplam tazminat

CEO maaş yüzdesi	74.5%
CEO görev süresi	1.3yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bronwyn Brophy O´Connor'un ücretlendirmesi Vitrolife'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-SEK 4b
Jun 30 2024	n/a	n/a	-SEK 4b
Mar 31 2024	n/a	n/a	-SEK 4b
Dec 31 2023	SEK 7m	SEK 6m	-SEK 4b

Tazminat ve Piyasa: Bronwyn 'nin toplam tazminatı ($USD 673.62K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.90M ).

Tazminat ve Kazançlar: Bronwyn şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Bronwyn Brophy O´Connor (50 yo)

1.3yrs

Görev süresi

SEK 7,439,000

Tazminat

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bronwyn Brophy O´Connor	CEO & President	1.3yrs	SEK 7.44m	0.014% € 372.5k
Patrik Tolf	Chief Financial Officer	2.8yrs	Veri yok	0.0096% € 250.2k
Claus Bisgaard	Senior Vice President of Technologies	no data	Veri yok	0.00028% € 7.3k
Guillermo Ferrando	Vice President Strategy & Corporate development	1.8yrs	Veri yok	Veri yok
Olivia Natens	Senior Vice President of Sales & Marketing	less than a year	Veri yok	Veri yok
Frank Pettersson	Acting Senior Vice President of HR & Sustainability	1.1yrs	Veri yok	0.0013% € 34.1k
Rickard Ericsson	Senior Vice President of Consumables	less than a year	Veri yok	0.0061% € 159.8k
Ricardo Capella	Senior Vice President Genetic Services	2.8yrs	Veri yok	0.0044% € 115.5k

1.3yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: VTFN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Henrik Blomquist	Director	5.5yrs	SEK 883.00k	0.0081% € 211.7k
Jon Sigurdsson	Chairman of the Board	9.8yrs	SEK 16.30m	0.022% € 585.2k
Lars Holmqvist	Independent Director	6.8yrs	SEK 450.00k	Veri yok
Pia Marions	Independent Director	11.6yrs	SEK 500.00k	0.0037% € 96.2k
Karen Soerensen	Independent Director	4.4yrs	SEK 500.00k	Veri yok

6.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VTFN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

Vitrolife Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vitrolife AB (Publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought €47k worth of stock

Recent updates

Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026

Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023)

Vitrolife AB (Publ) Announces Election Committee Appointments

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

Vitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023)

Now 19% undervalued after recent price drop

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

Now 24% undervalued

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Dividend of kr1.00 announced

Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022)

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Now 20% undervalued

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022)

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 15%

Chief Financial Officer recently bought €47k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Third quarter 2022 earnings released: EPS: kr0.80 (vs kr0.89 in 3Q 2021)

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Vitrolife AB (publ) Announces Election Committee Appointments

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Chief Financial Officer recently bought €48k worth of stock

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

Upcoming dividend of kr0.80 per share

Vitrolife AB (Publ) Proposes Dividend

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vitrolife AB (Publ) Proposes Dividend

Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020)

Vitrolife AB (publ) Approves Dividend for the Financial Year 2020

First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020)

Upcoming dividend of kr0.80 per share

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Revenue misses expectations

New 90-day high: €22.60

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021

New 90-day low: €20.14

Third quarter 2020 earnings released: EPS kr0.81

Revenue beats expectations

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021

Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021

New 90-day low: €20.16